{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:21:43Z","timestamp":1793924503230,"version":"4.8.0"},"reference-count":202,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773562"],"award-info":[{"award-number":["81773562"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82020108030"],"award-info":[{"award-number":["82020108030"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273782"],"award-info":[{"award-number":["82273782"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U21A20416"],"award-info":[{"award-number":["U21A20416"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.ejmech.2022.114898","type":"journal-article","created":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T13:02:10Z","timestamp":1667566930000},"page":"114898","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"P1","title":["New drug approvals for 2021: Synthesis and clinical applications"],"prefix":"10.1016","volume":"245","author":[{"given":"Shuo","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-Shu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Guang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Xue","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai-Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6771-9421","authenticated-orcid":false,"given":"Hong-Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2022.114898_bib1","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/d41573-021-00067-x","article-title":"FDA new drug approvals in Q1 2021","volume":"20","author":"Urquhart","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2022.114898_bib2","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/d41573-021-00126-3","article-title":"FDA new drug approvals in Q2 2021","volume":"20","author":"Urquhart","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2022.114898_bib3","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/d41573-021-00175-8","article-title":"FDA new drug approvals in Q3 2021","volume":"20","author":"Urquhart","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2022.114898_bib4","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/d41573-019-00014-x","article-title":"2018 FDA drug approvals","volume":"18","author":"Mullard","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2022.114898_bib5","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/d41573-020-00001-7","article-title":"2019 FDA drug approvals","volume":"19","author":"Mullard","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2022.114898_bib6","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/d41573-021-00002-0","article-title":"2020 FDA drug approvals","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2022.114898_bib7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/d41573-022-00001-9","article-title":"2021 FDA approvals","volume":"21","author":"Mullard","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2022.114898_bib8","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2022.114898_bib9","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2022.114898_bib10","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s40265-021-01488-z","article-title":"Voclosporin: first approval","volume":"81","author":"Heo","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2022.114898_bib11","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1200\/JCO.20.03433","article-title":"Umbralisib, a dual PI3K\u03b4\/CK1\u03b5 inhibitor in patients with relapsed or refractory indolent lymphoma","volume":"39","author":"Fowler","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2022.114898_bib12","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1038\/s41436-021-01287-7","article-title":"Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, Phase 3 extension study","volume":"23","author":"Savarirayan","year":"2021","journal-title":"Genet. Med."},{"key":"10.1016\/j.ejmech.2022.114898_bib13","first-page":"27","article-title":"Lighting the way for improved detection of ovarian cancer","volume":"327","author":"Voelker","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2022.114898_bib14","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.1002\/cam4.4089","article-title":"Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: pooled analysis of three randomized Phase 2 trials","volume":"10","author":"Ferrarotto","year":"2021","journal-title":"Cancer Med."},{"key":"10.1016\/j.ejmech.2022.114898_bib15","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s40265-021-01649-0","article-title":"Maralixibat: first approval","volume":"82","author":"Shirley","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2022.114898_bib16","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s40265-021-01496-z","article-title":"Vericiguat: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2022.114898_bib17","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s40265-020-01326-8","article-title":"Cabotegravir plus rilpivirine: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2022.114898_bib18","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s40265-020-01317-9","article-title":"Tepotinib: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2022.114898_bib19","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s40265-021-01504-2","article-title":"Umbralisib: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2022.114898_bib20","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s40265-021-01516-y","article-title":"Evinacumab: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2022.114898_bib21","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s40265-021-01550-w","article-title":"Loncastuximab tesirine: first approval","volume":"81","author":"Lee","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2022.114898_bib22","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s40265-021-01633-8","article-title":"Tisotumab vedotin: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2022.114898_bib23","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2022.114898_bib24","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a Phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2022.114898_bib25","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1021\/acs.jmedchem.7b01890","article-title":"The pharmacophore network: a computational method for exploring structure-activity relationships from a large chemical data set","volume":"61","author":"Metivier","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114898_bib26","doi-asserted-by":"crossref","first-page":"10375","DOI":"10.1021\/acs.jmedchem.8b00407","article-title":"Lead-like drugs: a perspective","volume":"61","author":"Raymer","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114898_bib27","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/nrd1467","article-title":"Fragment-based lead discovery","volume":"3","author":"Rees","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2022.114898_bib28","doi-asserted-by":"crossref","first-page":"9375","DOI":"10.1021\/acs.jmedchem.9b00359","article-title":"Overview of recent strategic advances in medicinal chemistry","volume":"62","author":"Wu","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114898_bib29","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1021\/jm040031v","article-title":"Fragment-based drug discovery","volume":"47","author":"Erlanson","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114898_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112667","article-title":"New drug approvals for 2019: synthesis and clinical applications","volume":"205","author":"Yuan","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114898_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113284","article-title":"New drug approvals for 2020: synthesis and clinical applications","volume":"215","author":"Yuan","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114898_bib32","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1007\/s00253-019-09641-1","article-title":"Insights into the anti-infective properties of prodiginines","volume":"103","author":"You","year":"2019","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.ejmech.2022.114898_bib33","first-page":"95","article-title":"HIV protease inhibitors: a review of molecular selectivity and toxicity","volume":"7","author":"Lv","year":"2015","journal-title":"HIV AIDS (Auckl)"},{"key":"10.1016\/j.ejmech.2022.114898_bib34","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2217\/fvl.12.56","article-title":"The molecular biology of HIV integrase","volume":"7","author":"Craigie","year":"2012","journal-title":"Future Virol."},{"key":"10.1016\/j.ejmech.2022.114898_bib35","first-page":"29","article-title":"New drugs for human African trypanosomiasis: a twenty first century success story","volume":"5","author":"Dickie","year":"2020","journal-title":"Trav. Med. Infect. Dis."},{"key":"10.1016\/j.ejmech.2022.114898_bib36","first-page":"5","article-title":"Treatment of vulvovaginal candidiasis: a review of the literature","volume":"24","author":"Dovnik","year":"2015","journal-title":"Acta Dermatovenerol. Alpina Pannonica Adriatica"},{"key":"10.1016\/j.ejmech.2022.114898_bib37","first-page":"53","article-title":"\u03b1- and \u03b2-1,3-Glucan synthesis and remodeling","volume":"425","author":"Wagener","year":"2020","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.ejmech.2022.114898_bib38","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ajt.12006","article-title":"CMV: prevention, diagnosis and therapy","volume":"13","author":"Kotton","year":"2013","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.ejmech.2022.114898_bib39","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2101016","article-title":"Cabotegravir for HIV prevention in cisgender men and transgender women","volume":"385","author":"Landovitz","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2022.114898_bib40","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/COH.0000000000000597","article-title":"Long-acting injectable cabotegravir for the prevention of HIV infection","volume":"15","author":"Clement","year":"2020","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.ejmech.2022.114898_bib41","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","article-title":"Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a Phase 3, randomised clinical trial","volume":"399","author":"Delany-Moretlwe","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2022.114898_bib42","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1021\/jm400645w","article-title":"Carbamoyl pyridone HIV-1 integrase inhibitors 3. A diastereomeric approach to chiral nonracemic tricyclic ring systems and the discovery of dolutegravir (S\/GSK1349572) and (S\/GSK1265744)","volume":"56","author":"Johns","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114898_bib43","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40265-019-1051-6","article-title":"Fexinidazole: first global approval","volume":"79","author":"Deeks","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2022.114898_bib44","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.pt.2017.12.002","article-title":"Fexinidazole: a new drug for African sleeping sickness on the horizon","volume":"34","author":"Pollastri","year":"2018","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.ejmech.2022.114898_bib45","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S2214-109X(21)00208-4","article-title":"Oral fexinidazole for stage 1 or early stage 2 African trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study","volume":"9","author":"Mesu","year":"2021","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.ejmech.2022.114898_bib46","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.bmcl.2010.12.040","article-title":"Compounds containing 2-substituted imidazole ring for treatment against human African trypanosomiasis","volume":"21","author":"Samant","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114898_bib47","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s40265-021-01571-5","article-title":"Ibrexafungerp: first approval","volume":"81","author":"Lee","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2022.114898_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.642358","article-title":"Ibrexafungerp, a novel oral triterpenoid antifungal in development: overview of antifungal activity against Candida glabrata","volume":"11","author":"Gamal","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.ejmech.2022.114898_bib49","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/cid\/ciab841","article-title":"Phase 2 randomized study of oral ibrexafungerp versus fluconazole in vulvovaginal candidiasis","volume":"74","author":"Nyirjesy","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejmech.2022.114898_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127661","article-title":"Ibrexafungerp: an orally active \u03b2-1, 3-glucan synthesis inhibitor, Bioorg","volume":"32","author":"Apgar","year":"2021","journal-title":"Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114898_bib51","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40265-022-01677-4","article-title":"Maribavir: first approval","volume":"82","author":"Kang","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2022.114898_bib52","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMoa1714656","article-title":"Maribavir for preemptive treatment of cytomegalovirus reactivation","volume":"381","author":"Maertens","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2022.114898_bib53","article-title":"Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a Phase 3 randomized clinical trial","author":"Avery","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejmech.2022.114898_bib54","series-title":"Arabinofuranosyl Benzimidazoles as Antiviral Agents","author":"Townsend","year":"1998"},{"key":"10.1016\/j.ejmech.2022.114898_bib55","series-title":"Process for Preparing Substituted Benzimidazole Compounds","author":"Freeman","year":"2001"},{"key":"10.1016\/j.ejmech.2022.114898_bib56","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41569-021-00549-w","article-title":"Pharmacogenetics to guide cardiovascular drug therapy","volume":"18","author":"Duarte","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.ejmech.2022.114898_bib57","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/S0140-6736(05)66621-4","article-title":"Heart failure","volume":"365","author":"McMurray","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2022.114898_bib58","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/164_2016_100","article-title":"Novel sGC stimulators and sGC activators for the treatment of heart failure","volume":"243","author":"Breitenstein","year":"2017","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114898_bib59","article-title":"Development of vericiguat: the first soluble guanylate cyclase (sGC) stimulator launched for heart failure with reduced ejection fraction (HFrEF), Biomed","volume":"149","author":"Xia","year":"2022","journal-title":"Pharma"},{"key":"10.1016\/j.ejmech.2022.114898_bib60","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1001\/jama.2020.15922","article-title":"Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial","volume":"324","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2022.114898_bib61","doi-asserted-by":"crossref","first-page":"5146","DOI":"10.1021\/acs.jmedchem.7b00449","article-title":"Discovery of the soluble guanylate cyclase stimulator vericiguat (BAY 1021189) for the treatment of chronic heart failure","volume":"60","author":"Follmann","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114898_bib62","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1007\/s13296-021-00463-4","article-title":"The effect of geometry on structural behavior of buildings with steel plate shear wall system subjected to blast loading","volume":"21","author":"Shabanlou","year":"2021","journal-title":"Int. J. Steel. Struct."},{"key":"10.1016\/j.ejmech.2022.114898_bib63","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.mcna.2018.10.003","article-title":"Migraine and tension-type headache, Med","volume":"103","author":"Burch","year":"2019","journal-title":"Clin. N. Am."},{"key":"10.1016\/j.ejmech.2022.114898_bib64","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.neurol.2021.06.003","article-title":"CGRP and migraine: from bench to bedside","volume":"177","author":"Edvinsson","year":"2021","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.ejmech.2022.114898_bib65","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1053\/j.ajkd.2017.05.018","article-title":"Treatment of uremic pruritus: a systematic review","volume":"70","author":"Simonsen","year":"2017","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ejmech.2022.114898_bib66","first-page":"527","article-title":"Progressive multiple sclerosis: from pathogenic mechanisms to treatment","volume":"140","author":"Correale","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.ejmech.2022.114898_bib67","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.bbi.2016.12.010","article-title":"The microbiome, immunity, and schizophrenia and bipolar disorder","volume":"62","author":"Dickerson","year":"2017","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.ejmech.2022.114898_bib68","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/1060028013510699","article-title":"A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD)","volume":"48","author":"Sharma","year":"2014","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ejmech.2022.114898_bib69","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40265-021-01644-5","article-title":"Atogepant: first approval","volume":"82","author":"Deeks","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2022.114898_bib70","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1056\/NEJMoa2035908","article-title":"Atogepant for the preventive treatment of migraine","volume":"385","author":"Ailani","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2022.114898_bib71","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s10194-022-01391-2","article-title":"The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials","volume":"23","author":"Tao","year":"2022","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.ejmech.2022.114898_bib72","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.15499","article-title":"Rates of response to atogepant for migraine prophylaxis among adults: a secondary analysis of a randomized clinical trial","volume":"5","author":"Lipton","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ejmech.2022.114898_bib73","series-title":"Process for Making CGRP Receptor Antagonists","author":"Chen","year":"2013"},{"key":"10.1016\/j.ejmech.2022.114898_bib74","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1007\/s40265-021-01619-6","article-title":"Difelikefalin: first approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2022.114898_bib75","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.10339","article-title":"Efficacy and safety of difelikefalin in Japanese patients with moderate to severe pruritus receiving hemodialysis: a randomized clinical trial","volume":"5","author":"Narita","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ejmech.2022.114898_bib76","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1912770","article-title":"A Phase 3 trial of difelikefalin in hemodialysis patients with pruritus","volume":"382","author":"Fishbane","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2022.114898_bib77","series-title":"Method for Producing Synthetic Pentapeptide","author":"Mei","year":"2014"},{"key":"10.1016\/j.ejmech.2022.114898_bib78","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s40265-021-01523-z","article-title":"Ponesimod: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2022.114898_bib79","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1136\/jnnp-2013-307538","article-title":"Are more sphingosine 1-phosphate receptor agonists a better therapeutic option against multiple sclerosis?","volume":"85","author":"Mori","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ejmech.2022.114898_bib80","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/jamaneurol.2021.0405","article-title":"Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator Phase 3 OPTIMUM study: a randomized clinical trial","volume":"78","author":"Kappos","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ejmech.2022.114898_bib81","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1021\/jm100181s","article-title":"2-Imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists","volume":"53","author":"Bolli","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114898_bib82","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s40265-021-01568-0","article-title":"Olanzapine\/samidorphan: first approval","volume":"81","author":"Paik","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2022.114898_bib83","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/JCP.0000000000000770","article-title":"A pilot study of the usefulness of a single olanzapine plasma concentration as an indicator of early drug effect in a small sample of first-episode psychosis patients","volume":"37","author":"Zabala","year":"2017","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.ejmech.2022.114898_bib84","first-page":"5139","article-title":"A review of samidorphan: a novel opioid antagonist","volume":"11","author":"Chaudhary","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.ejmech.2022.114898_bib85","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19m12786","article-title":"Olanzapine plus samidorphan (ALKS 3831) in schizophrenia and comorbid alcohol use disorder: a Phase 2, randomized clinical trial","volume":"81","author":"Brunette","year":"2020","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.ejmech.2022.114898_bib86","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1016\/j.bmcl.2005.02.032","article-title":"Synthesis and opioid receptor binding properties of a highly potent 4-hydroxy analogue of naltrexone","volume":"15","author":"Wentland","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114898_bib87","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/j.bmcl.2009.02.078","article-title":"Syntheses of novel high affinity ligands for opioid receptors","volume":"19","author":"Wentland","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114898_bib88","first-page":"288","article-title":"Dose proportionality and steady-state pharmacokinetics of serdexmethylphenidate\/dexmethylphenidate, a novel prodrug combination to treat attention-deficit\/hyperactivity disorder, J. Child Adolesc","volume":"32","author":"Braeckman","year":"2022","journal-title":"Psychopharmacol."},{"key":"10.1016\/j.ejmech.2022.114898_bib89","first-page":"597","article-title":"A randomized, controlled laboratory classroom study of serdexmethylphenidate and d-methylphenidate capsules in children with attention-deficit\/hyperactivity disorder, J. Child Adolesc","volume":"31","author":"Kollins","year":"2021","journal-title":"Psychopharmacol."},{"key":"10.1016\/j.ejmech.2022.114898_bib90","series-title":"Compositions Comprising Methylphenidate-Prodrugs, Processes of Making and Using the Same","author":"Mickle","year":"2020"},{"key":"10.1016\/j.ejmech.2022.114898_bib91","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s40272-021-00453-3","article-title":"Viloxazine: pediatric first approval","volume":"23","author":"Lamb","year":"2021","journal-title":"Pediatr. Drugs"},{"key":"10.1016\/j.ejmech.2022.114898_bib92","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.789982","article-title":"Viloxazine in the treatment of attention deficit hyperactivity disorder","volume":"12","author":"Edinoff","year":"2021","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.ejmech.2022.114898_bib93","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.clinthera.2020.05.021","article-title":"A Phase III, randomized, placebo-controlled trial to assess the efficacy and safety of once-daily SPN-812 (viloxazine extended-release) in the treatment of attention-deficit\/hyperactivity disorder in school-age children","volume":"42","author":"Nasser","year":"2020","journal-title":"Clin. Therapeut."},{"key":"10.1016\/j.ejmech.2022.114898_bib94","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.tet.2015.12.015","article-title":"Lewis acid mediated intramolecular C-O bond formation of alkanol-epoxide leading to substituted morpholine and 1, 4-oxazepane derivatives: total synthesis of (\u00b1)-viloxazine","volume":"72","author":"Ghosh","year":"2016","journal-title":"Tetrahedron"},{"key":"10.1016\/j.ejmech.2022.114898_bib95","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.reprotox.2016.10.001","article-title":"Metabolism disrupting chemicals and metabolic disorders","volume":"68","author":"Heindel","year":"2017","journal-title":"Reprod. Toxicol."},{"key":"10.1016\/j.ejmech.2022.114898_bib96","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1001\/jama.2021.21392","article-title":"Contraception selection, effectiveness, and adverse effects: a review","volume":"326","author":"Teal","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2022.114898_bib97","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.3390\/ijms19092591","article-title":"Molecular pathways of estrogen receptor action","volume":"19","author":"Pakdel","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2022.114898_bib98","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ecl.2020.05.012","article-title":"Diabetes insipidus: an update","volume":"49","author":"Refardt","year":"2020","journal-title":"Endocrinol. Metabol. Clin"},{"key":"10.1016\/j.ejmech.2022.114898_bib99","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/bs.vh.2018.10.005","article-title":"Adipocyte mineralocorticoid receptor","volume":"109","author":"Infante","year":"2019","journal-title":"Vitam. Horm."},{"key":"10.1016\/j.ejmech.2022.114898_bib100","doi-asserted-by":"crossref","first-page":"5625","DOI":"10.3390\/jcm10235625","article-title":"Estetrol: a new choice for contraception","volume":"10","author":"Fruzzetti","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejmech.2022.114898_bib101","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s40265-022-01738-8","article-title":"Estetrol\/drospirenone: a review in oral contraception","volume":"82","author":"Lee","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2022.114898_bib102","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.contraception.2021.05.002","article-title":"Estetrol-drospirenone combination oral contraceptive: north American Phase 3 efficacy and safety results","volume":"104","author":"Creinin","year":"2021","journal-title":"Contraception"},{"key":"10.1016\/j.ejmech.2022.114898_bib103","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/13697130802054078","article-title":"A new route of synthesis of estetrol","volume":"11","author":"Warmerdam","year":"2008","journal-title":"Climacteric"},{"key":"10.1016\/j.ejmech.2022.114898_bib104","series-title":"Synthesis of Estetrol via Estrone Derived Steroids","author":"Verhaar","year":"2004"},{"key":"10.1016\/j.ejmech.2022.114898_bib105","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s40265-021-01599-7","article-title":"Finerenone: first approval","volume":"81","author":"Frampton","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2022.114898_bib106","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2022.114898_bib107","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"G. Mineralocorticoid Receptor antagonist tolerability study-diabetic nephropathy study, effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2022.114898_bib108","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/cmdc.201200081","article-title":"Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases","volume":"7","author":"Barfacker","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2022.114898_bib109","first-page":"5","article-title":"Drug therapy for hereditary cancers, Hered. Cancer in","volume":"9","author":"Imyanitov","year":"2011","journal-title":"Clin. Pract."},{"key":"10.1016\/j.ejmech.2022.114898_bib110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymgme.2015.11.010","article-title":"Molybdenum cofactor deficiency","volume":"117","author":"Atwal","year":"2016","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.ejmech.2022.114898_bib111","first-page":"1","article-title":"Pruritus: progress toward pathogenesis and treatment","volume":"2018","author":"Song","year":"2018","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.ejmech.2022.114898_bib112","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1007\/s40265-021-01594-y","article-title":"Odevixibat: first approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2022.114898_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2021.101751","article-title":"Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: phase 2 study","volume":"45","author":"Baumann","year":"2021","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"10.1016\/j.ejmech.2022.114898_bib114","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S2468-1253(22)00093-0","article-title":"Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, Phase 3 trial","volume":"7","author":"Thompson","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2022.114898_bib115","series-title":"Benzothiazepine and Benzothiadiazepine Derivatives with Ileal Bile Acid Transport (Ibat) Inhibitory Activity for the Treatment Hyperlipidaemia","author":"Starke","year":"2003"},{"key":"10.1016\/j.ejmech.2022.114898_bib116","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s40265-021-01520-2","article-title":"Fosdenopterin: first approval","volume":"81","author":"Kang","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2022.114898_bib117","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/jimd.12421","article-title":"Regulatory news: nulibry (fosdenopterin) approved to reduce the risk of mortality in patients with molybdenum cofactor deficiency type A: FDA approval summary","volume":"44","author":"Farrell","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ejmech.2022.114898_bib118","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1021\/jm301855r","article-title":"Synthesis of cyclic pyranopterin monophosphate, a biosynthetic intermediate in the molybdenum cofactor pathway","volume":"56","author":"Clinch","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114898_bib119","first-page":"6","article-title":"Maralixibat relieves chronic cholestasis in children","volume":"19","author":"Barranco","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2022.114898_bib120","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/S0140-6736(21)01256-3","article-title":"Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised Phase 2 study","volume":"398","author":"Gonzales","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2022.114898_bib121","doi-asserted-by":"crossref","DOI":"10.1021\/jm0402162","article-title":"Discovery of potent, nonsystemic apical sodium-codependent bile acid transporter inhibitors (Part 2)","volume":"48","author":"Huang","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114898_bib122","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1159\/000494931","article-title":"Recent advances in clinical allergy and immunology","volume":"177","author":"Simon","year":"2018","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.ejmech.2022.114898_bib123","doi-asserted-by":"crossref","first-page":"7319","DOI":"10.3390\/ijms21197319","article-title":"Immunopathogenesis of ANCA-associated vasculitis","volume":"21","author":"Kronbichler","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2022.114898_bib124","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.3892\/etm.2021.10548","article-title":"Role of C5a and C5Ar in doxorubicin-induced cardiomyocyte senescence","volume":"22","author":"Wen","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.ejmech.2022.114898_bib125","first-page":"7","article-title":"Oral complications of chronic graft-versus-host disease","author":"Fall-Dickson","year":"2019","journal-title":"J. Natl. Cancer Inst. Monogr."},{"key":"10.1016\/j.ejmech.2022.114898_bib126","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/nbt1310","article-title":"A ROCK inhibitor permits survival of dissociated human embryonic stem cells","volume":"25","author":"Watanabe","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejmech.2022.114898_bib127","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1681\/ASN.2013010026","article-title":"The pathogenesis of lupus nephritis","volume":"24","author":"Lech","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejmech.2022.114898_bib128","first-page":"137","article-title":"Calcineurin, cell commun","volume":"18","author":"Creamer","year":"2020","journal-title":"Signal"},{"key":"10.1016\/j.ejmech.2022.114898_bib129","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s40265-021-01643-6","article-title":"Avacopan: first approval","volume":"82","author":"Lee","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2022.114898_bib130","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/13543784.2018.1472234","article-title":"Avacopan in the treatment of ANCA-associated vasculitis, expert opin","volume":"27","author":"Tesar","year":"2018","journal-title":"Invest. Drugs"},{"key":"10.1016\/j.ejmech.2022.114898_bib131","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2022.114898_bib132","series-title":"Processes and Intermediates for Preparing C5aR Antagonists","author":"Fan","year":"2016"},{"key":"10.1016\/j.ejmech.2022.114898_bib133","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1007\/s40265-021-01593-z","article-title":"Belumosudil: first approval","volume":"81","author":"Blair","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2022.114898_bib134","article-title":"Belumosudil with ROCK-2 inhibition: chemical and therapeutic development to FDA approval for the treatment of chronic graft-versus-host disease","volume":"70","author":"Ali","year":"2022","journal-title":"Curr. Res. Transl. Med."},{"key":"10.1016\/j.ejmech.2022.114898_bib135","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1182\/blood.2021012021","article-title":"Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar study","volume":"138","author":"Cutler","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2022.114898_bib136","series-title":"Rho Kinase Inhibitors","author":"Sweetnam","year":"2010"},{"key":"10.1016\/j.ejmech.2022.114898_bib137","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1080\/1744666X.2021.1967747","article-title":"Voclosporin: a novel calcineurin inhibitor for the management of lupus nephritis","volume":"17","author":"Mejia-Vilet","year":"2021","journal-title":"Expet Rev. Clin. Immunol."},{"key":"10.1016\/j.ejmech.2022.114898_bib138","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, Phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2022.114898_bib139","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1055\/s-0031-1289616","article-title":"Organozirconium chemistry on cyclosporin: a novel process for the highly stereoselective synthesis of (E)-ISA247 (voclosporin) and close analogues","volume":"44","author":"Yang","year":"2011","journal-title":"Synthesis"},{"key":"10.1016\/j.ejmech.2022.114898_bib140","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.2174\/0929867325666171129215610","article-title":"Overview on anticancer drug design and development","volume":"25","author":"Olgen","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114898_bib141","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.2174\/0929867325666180713155702","article-title":"Drug repurposing in the development of anticancer agents","volume":"26","author":"Olgen","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114898_bib142","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nrc3185","article-title":"Balancing repair and tolerance of DNA damage caused by alkylating agents","volume":"12","author":"Fu","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2022.114898_bib143","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1158\/1078-0432.CCR-17-2452","article-title":"Resistance mechanisms to targeted therapies in ROS1(+) and ALK(+) non-small cell lung cancer","volume":"24","author":"McCoach","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114898_bib144","article-title":"Signal transduction--receptors, mediators, and genes","volume":"2","author":"Entschladen","year":"2009","journal-title":"Sci. Signal."},{"key":"10.1016\/j.ejmech.2022.114898_bib145","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.180112","article-title":"Structural insights into the functional diversity of the CDK-cyclin family","volume":"8","author":"Wood","year":"2018","journal-title":"Open Biol"},{"key":"10.1016\/j.ejmech.2022.114898_bib146","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.canlet.2016.01.043","article-title":"Tumor microenvironment and therapeutic response","volume":"387","author":"Wu","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2022.114898_bib147","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40265-021-01662-3","article-title":"Asciminib: first approval","volume":"82","author":"Deeks","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2022.114898_bib148","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2022.114898_bib149","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1182\/blood.2021013257","article-title":"Asciminib for CML: same target, new arrow","volume":"138","author":"Schiffer","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2022.114898_bib150","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.2020009984","article-title":"A Phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs","volume":"138","author":"Rea","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2022.114898_bib151","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","article-title":"Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1","volume":"61","author":"Schoepfer","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114898_bib152","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1007\/s40265-021-01606-x","article-title":"Belzutifan: first approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2022.114898_bib153","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa2110051","article-title":"Belzutifan, a potent HIF2\u03b1 inhibitor, in the pacak-Zhuang syndrome","volume":"385","author":"Kamihara","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2022.114898_bib154","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von Hippel-Lindau disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2022.114898_bib155","doi-asserted-by":"crossref","first-page":"6876","DOI":"10.1021\/acs.jmedchem.9b00719","article-title":"3-[(1S, 2S, 3R)-2, 3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzo nitrile (PT2977), a hypoxia-inducible factor 2 \u03b1 (HIF-2\u03b1) inhibitor for the treatment of clear cell renal cell carcinoma","volume":"62","author":"Xu","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114898_bib156","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s40265-021-01567-1","article-title":"Infigratinib: first approval","volume":"81","author":"Kang","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2022.114898_bib157","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/13543784.2021.1864320","article-title":"Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma","volume":"30","author":"Botrus","year":"2021","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2022.114898_bib158","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","article-title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, Phase 2 study","volume":"6","author":"Javle","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2022.114898_bib159","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1021\/jm2006222","article-title":"Discovery of 3-(2, 6-dichloro-3, 5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamin o]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase","volume":"54","author":"Guagnano","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114898_bib160","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s40265-021-01522-0","article-title":"Melphalan flufenamide (melflufen): first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2022.114898_bib161","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.2147\/DDDT.S295215","article-title":"Spotlight on melphalan flufenamide: an up-and-coming therapy for the treatment of myeloma","volume":"15","author":"Morabito","year":"2021","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejmech.2022.114898_bib162","article-title":"Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes","volume":"15","author":"Byrgazov","year":"2021","journal-title":"BoneKEy Rep."},{"key":"10.1016\/j.ejmech.2022.114898_bib163","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/bjh.17302","article-title":"Melflufen plus dexamethasone in relapsed\/refractory multiple myeloma: long-term survival follow-up from the Phase II study O-12-M1","volume":"193","author":"Bringhen","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejmech.2022.114898_bib164","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S2352-3026(21)00381-1","article-title":"Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, Phase 3 study","volume":"9","author":"Schjesvold","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ejmech.2022.114898_bib165","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1021\/acs.oprd.9b00116","article-title":"Development of a safe process for manufacturing of the potent anticancer agent melflufen hydrochloride","volume":"23","author":"Cotton","year":"2019","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.ejmech.2022.114898_bib166","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1007\/s40265-021-01632-9","article-title":"Mobocertinib: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2022.114898_bib167","first-page":"61","article-title":"Spotlight on mobocertinib (TAK-788) in NSCLC with EGFR exon 20 insertion mutations","volume":"12","author":"Zhang","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejmech.2022.114898_bib168","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.3390\/biomedicines9121938","article-title":"Discovery, development, inventions, and patent trends on mobocertinib succinate: the first-in-class oral treatment for NSCLC with EGFR exon 20 insertions","volume":"9","author":"Imran","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejmech.2022.114898_bib169","article-title":"Targeting EGFR exon 20 insertion mutation in non-small cell lung cancer: amivantamab and mobocertinib","author":"Russell","year":"2022","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ejmech.2022.114898_bib170","series-title":"Pharmaceutical Salts of Pyrimidine Derivatives and Method of Treating Disorders","author":"Durak","year":"2019"},{"key":"10.1016\/j.ejmech.2022.114898_bib171","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s40265-021-01574-2","article-title":"Sotorasib: first approval","volume":"81","author":"Blair","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2022.114898_bib172","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRAS(G12C) Inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2022.114898_bib173","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(21)00605-7","article-title":"Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, Phase 2 trial","volume":"23","author":"Fakih","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2022.114898_bib174","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113082","article-title":"Design, synthesis and pharmacological evaluation of bicyclic and tetracyclic pyridopyrimidinone analogues as new KRAS(G12C) inhibitors","volume":"213","author":"Xiao","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114898_bib175","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1021\/acsmedchemlett.1c00330","article-title":"Improved synthesis of new FDA-approved treatment for KRAS G12C mutation in non-small cell lung cancer","volume":"12","author":"Kargbo","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114898_bib176","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1021\/acs.jmedchem.9b01180","article-title":"Discovery of a covalent inhibitor of KRAS(G12C) (AMG 510) for the treatment of solid tumors","volume":"63","author":"Lanman","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114898_bib177","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1158\/1078-0432.CCR-21-1566","article-title":"FDA approval summary: capmatinib and tepotinib for the treatment of metastatic NSCLC harboring MET exon 14 skipping mutations or alterations","volume":"28","author":"Mathieu","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114898_bib178","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/S2213-2600(20)30154-5","article-title":"Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, Phase 1b\/2, multicentre, randomised trial","volume":"8","author":"Wu","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ejmech.2022.114898_bib179","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2022.114898_bib180","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3390\/molecules24061173","article-title":"Synthesis, evaluation, and mechanism study of new tepotinib derivatives as antiproliferative agents","volume":"24","author":"Zhang","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2022.114898_bib181","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.bmcl.2015.02.002","article-title":"Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors","volume":"25","author":"Dorsch","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114898_bib182","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s40265-017-0825-y","article-title":"Tivozanib: first global approval","volume":"77","author":"Kim","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2022.114898_bib183","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1758835920923818","article-title":"Tivozanib in renal cell carcinoma: a new approach to previously treated disease","volume":"12","author":"Salgia","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.ejmech.2022.114898_bib184","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1470-2045(19)30735-1","article-title":"Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a Phase 3, multicentre, randomised, controlled, open-label study","volume":"21","author":"Rini","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2022.114898_bib185","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.bmcl.2015.03.088","article-title":"Design, synthesis and biological evaluation of deuterated tivozanib for improving pharmacokinetic properties","volume":"25","author":"Guo","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114898_bib186","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.4028\/www.scientific.net\/AMR.396-398.1490","article-title":"Synthesis of anti-cancer targeted therapies drug tivozanib","volume":"396\u2013398","author":"Liu","year":"2011","journal-title":"Adv. Mater. Res."},{"key":"10.1016\/j.ejmech.2022.114898_bib187","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.3987\/COM-16-13555","article-title":"A new and practical synthesis of tivozanib","volume":"92","author":"Mao","year":"2016","journal-title":"Heterocycles"},{"key":"10.1016\/j.ejmech.2022.114898_bib188","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s40265-021-01508-y","article-title":"Trilaciclib: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2022.114898_bib189","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101206","article-title":"Concerning FDA approval of trilaciclib (Cosela) in extensive-stage small-cell lung cancer","volume":"14","author":"Powell","year":"2021","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.ejmech.2022.114898_bib190","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/13696998.2021.2014163","article-title":"Trilaciclib and the economic value of multilineage myeloprotection from chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer treated with first-line chemotherapy","volume":"24","author":"Abraham","year":"2021","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.ejmech.2022.114898_bib191","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s12325-020-01538-0","article-title":"Myelopreservation with trilaciclib in patients receiving topotecan for small cell lung cancer: results from a randomized, double-blind, placebo-controlled Phase II study","volume":"38","author":"Hart","year":"2021","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ejmech.2022.114898_bib192","series-title":"Synthesis of N-(heteroaryl)-pyrrolo[3, 2-D]pyrimidin-2-Amines","author":"Smith","year":"2018"},{"key":"10.1016\/j.ejmech.2022.114898_bib193","doi-asserted-by":"crossref","first-page":"5332","DOI":"10.1182\/bloodadvances.2021005132","article-title":"Integrated safety analysis of umbralisib, a dual PI3K\u03b4\/CK1\u03f5 inhibitor, in relapsed\/refractory lymphoid malignancies","volume":"5","author":"Davids","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejmech.2022.114898_bib194","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S2352-3026(18)30196-0","article-title":"Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre Phase 1-1b study","volume":"6","author":"Davids","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ejmech.2022.114898_bib195","series-title":"Selective PI3K \u03b4 Inhibitors","author":"Vakkalanka","year":"2014"},{"key":"10.1016\/j.ejmech.2022.114898_bib196","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s11427-018-9342-2","article-title":"Artificial intelligence in drug design","volume":"61","author":"Zhong","year":"2018","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.ejmech.2022.114898_bib197","first-page":"915","article-title":"Contemporary medicinal-chemistry strategies for discovery of blood coagulation factor Xa inhibitors, Expert Opin","volume":"14","author":"Hao","year":"2019","journal-title":"Drug Discovery"},{"key":"10.1016\/j.ejmech.2022.114898_bib198","doi-asserted-by":"crossref","first-page":"375","DOI":"10.4155\/fmc-2018-0397","article-title":"Discovery of novel anti-influenza agents via contemporary medicinal chemistry strategies (2014-2018 update)","volume":"11","author":"Jia","year":"2019","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114898_bib199","doi-asserted-by":"crossref","first-page":"14895","DOI":"10.1021\/acs.jmedchem.1c01452","article-title":"Discovery of new 4-indolyl quinazoline derivatives as highly potent and orally bioavailable P-glycoprotein inhibitors","volume":"64","author":"Yuan","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114898_bib200","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1021\/acs.orglett.1c00129","article-title":"Cu(OTf)2-catalyzed intramolecular radical cascade reactions for the diversity-oriented synthesis of quinoline-annulated polyheterocyclic frameworks","volume":"23","author":"Yuan","year":"2021","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2022.114898_bib201","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/adsc.201801226","article-title":"Br\u00f8nsted acid\u2010catalyzed direct C(sp2)-H heteroarylation enabling the synthesis of structurally diverse biaryl derivatives","volume":"361","author":"Yuan","year":"2018","journal-title":"Adv. Synth. Catal."},{"key":"10.1016\/j.ejmech.2022.114898_bib202","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.cclet.2020.03.028","article-title":"New techniques and strategies in drug discovery","volume":"31","author":"Du","year":"2020","journal-title":"Chin. Chem. Lett."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422008005?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422008005?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:45:55Z","timestamp":1759329955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523422008005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":202,"alternative-id":["S0223523422008005"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114898","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New drug approvals for 2021: Synthesis and clinical applications","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114898","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114898"}}